163 related articles for article (PubMed ID: 36290871)
21. Lutetium DOTATATE whole body scans: A novel approach for evaluation of neuroendocrine tumors.
Singh N; Krishna B; Vyas M; Venkatesh M; Banerjee S; Das T; Nair KV; Sudipta
Indian J Nucl Med; 2011 Jul; 26(3):135-8. PubMed ID: 23326064
[TBL] [Abstract][Full Text] [Related]
22. An Analysis for Therapeutic Doses of Patients with Neuroendocrine Tumor Treated with Lutetium 177 (
Kovan B; Özkan ZG; Demir B; Tunçman D; Işik EG; Şimşek DH; Büyükkaya F; Türkmen C; Şanli Y
Cancer Biother Radiopharm; 2022 Feb; 37(1):17-22. PubMed ID: 34134512
[No Abstract] [Full Text] [Related]
23. Phase 3 Trial of
Strosberg J; El-Haddad G; Wolin E; Hendifar A; Yao J; Chasen B; Mittra E; Kunz PL; Kulke MH; Jacene H; Bushnell D; O'Dorisio TM; Baum RP; Kulkarni HR; Caplin M; Lebtahi R; Hobday T; Delpassand E; Van Cutsem E; Benson A; Srirajaskanthan R; Pavel M; Mora J; Berlin J; Grande E; Reed N; Seregni E; Öberg K; Lopera Sierra M; Santoro P; Thevenet T; Erion JL; Ruszniewski P; Kwekkeboom D; Krenning E;
N Engl J Med; 2017 Jan; 376(2):125-135. PubMed ID: 28076709
[TBL] [Abstract][Full Text] [Related]
24. High clinical and morphologic response using
Kong G; Callahan J; Hofman MS; Pattison DA; Akhurst T; Michael M; Eu P; Hicks RJ
Eur J Nucl Med Mol Imaging; 2017 Mar; 44(3):476-489. PubMed ID: 27678267
[TBL] [Abstract][Full Text] [Related]
25. Lutetium therapy-induced carcinoid crisis: A case report and review of literature.
Yadav SK; Jha CK; Patil S; Datta D; Mishra A; Pradhan PK
J Cancer Res Ther; 2020 Dec; 16(Supplement):S206-S208. PubMed ID: 33380679
[TBL] [Abstract][Full Text] [Related]
26. Case Report: Re-Treatment With Lu-DOTATATE in Neuroendocrine Tumors.
Vida Navas EM; Martínez Lorca A; Sancho Gutiérrez A; Sanz Gómez L; Navarro Martínez T; Grande Pulido E; Carrato Mena A; Gajate Borau P
Front Endocrinol (Lausanne); 2021; 12():676973. PubMed ID: 33935979
[TBL] [Abstract][Full Text] [Related]
27. Long-Term Efficacy, Survival, and Safety of [
Brabander T; van der Zwan WA; Teunissen JJM; Kam BLR; Feelders RA; de Herder WW; van Eijck CHJ; Franssen GJH; Krenning EP; Kwekkeboom DJ
Clin Cancer Res; 2017 Aug; 23(16):4617-4624. PubMed ID: 28428192
[No Abstract] [Full Text] [Related]
28. Bilateral Orbital Soft-Tissue Metastases from Renal Neuroendocrine Tumor: Successful Theranostic Application of
Parghane RV; Basu S
J Nucl Med Technol; 2019 Jun; 47(2):171-172. PubMed ID: 30139884
[TBL] [Abstract][Full Text] [Related]
29. Peptide Receptor Radiotherapy Comes of Age.
Al-Toubah T; Strosberg J
Endocrinol Metab Clin North Am; 2018 Sep; 47(3):615-625. PubMed ID: 30098719
[TBL] [Abstract][Full Text] [Related]
30. Somatostatin receptor imaging in non-(131)I-avid metastatic differentiated thyroid carcinoma for determining the feasibility of peptide receptor radionuclide therapy with (177)Lu-DOTATATE: low fraction of patients suitable for peptide receptor radionuclide therapy and evidence of chromogranin A level-positive neuroendocrine differentiation.
Jois B; Asopa R; Basu S
Clin Nucl Med; 2014 Jun; 39(6):505-10. PubMed ID: 24662668
[TBL] [Abstract][Full Text] [Related]
31. The role of baseline Ga-68 DOTATATE positron emission tomography/computed tomography in the prediction of response to fixed-dose peptide receptor radionuclide therapy with Lu-177 DOTATATE.
Soydal Ç; Peker A; Özkan E; Küçük ÖN; Kir MK
Turk J Med Sci; 2016 Feb; 46(2):409-13. PubMed ID: 27511504
[TBL] [Abstract][Full Text] [Related]
32. Image Findings of a Rare Case of Neuroendocrine Tumor Metastatic to Orbital Extraocular Muscle in Gallium-68 DOTANOC Positron Emission Tomography/Computed Tomography and Therapy with Lutetium-177 DOTATATE.
Kamaleshwaran KK; Joseph J; Upadhya I; Shinto AS
Indian J Nucl Med; 2017; 32(2):125-127. PubMed ID: 28533641
[TBL] [Abstract][Full Text] [Related]
33. Effectiveness of radiolabelled somatostatin analogues (
Medina-Ornelas SS; García-Pérez FO
Rev Esp Med Nucl Imagen Mol; 2017; 36(3):166-174. PubMed ID: 27890514
[TBL] [Abstract][Full Text] [Related]
34. Treatment with
Estorch M
Rev Esp Med Nucl Imagen Mol; 2017; 36(2):69-71. PubMed ID: 28257748
[No Abstract] [Full Text] [Related]
35. Intra-arterial versus standard intravenous administration of lutetium-177-DOTA-octreotate in patients with NET liver metastases: study protocol for a multicenter, randomized controlled trial (LUTIA trial).
Ebbers SC; Braat AJAT; Moelker A; Stokkel MPM; Lam MGEH; Barentsz MW
Trials; 2020 Feb; 21(1):141. PubMed ID: 32024533
[TBL] [Abstract][Full Text] [Related]
36. Cost-effectiveness of Lutetium [
Leeuwenkamp O; Smith-Palmer J; Ortiz R; Werner A; Valentine W; Blachier M; Walter T
J Med Econ; 2020 Dec; 23(12):1534-1541. PubMed ID: 32990484
[TBL] [Abstract][Full Text] [Related]
37. Phase I Trial of Well-Differentiated Neuroendocrine Tumors (NETs) with Radiolabeled Somatostatin Antagonist
Reidy-Lagunes D; Pandit-Taskar N; O'Donoghue JA; Krebs S; Staton KD; Lyashchenko SK; Lewis JS; Raj N; Gönen M; Lohrmann C; Bodei L; Weber WA
Clin Cancer Res; 2019 Dec; 25(23):6939-6947. PubMed ID: 31439583
[TBL] [Abstract][Full Text] [Related]
38. Overview and Current Status of Peptide Receptor Radionuclide Therapy.
Bushnell DL; Bodeker KL
Surg Oncol Clin N Am; 2020 Apr; 29(2):317-326. PubMed ID: 32151363
[TBL] [Abstract][Full Text] [Related]
39.
Strosberg JR; Caplin ME; Kunz PL; Ruszniewski PB; Bodei L; Hendifar A; Mittra E; Wolin EM; Yao JC; Pavel ME; Grande E; Van Cutsem E; Seregni E; Duarte H; Gericke G; Bartalotta A; Mariani MF; Demange A; Mutevelic S; Krenning EP;
Lancet Oncol; 2021 Dec; 22(12):1752-1763. PubMed ID: 34793718
[TBL] [Abstract][Full Text] [Related]
40. Discordance Between Histopathologic Grading and Dual-Tracer PET/CT Findings in Metastatic NETs and Outcome of
Adnan A; Basu S
J Nucl Med Technol; 2022 Sep; 50(3):248-255. PubMed ID: 34876476
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
